StemCell Therapy

BioTelemetry (NASDAQ: BEAT) and Signal Genetics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Institutional and Insider Ownership

78.0% of BioTelemetry shares are held by institutional investors. Comparatively, 20.7% of Signal Genetics shares are held by institutional investors. 9.6% of BioTelemetry shares are held by insiders. Comparatively, 44.4% of Signal Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

BioTelemetry has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Signal Genetics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for BioTelemetry and Signal Genetics, as provided by MarketBeat.com.

BioTelemetry currently has a consensus price target of $45.75, indicating a potential upside of 21.19%. Signal Genetics has a consensus price target of $23.00, indicating a potential upside of 156.70%. Given Signal Genetics higher possible upside, analysts clearly believe Signal Genetics is more favorable than BioTelemetry.

Valuation and Earnings

This table compares BioTelemetry and Signal Genetics revenue, earnings per share (EPS) and valuation.

BioTelemetry has higher revenue and earnings than Signal Genetics.

Profitability

This table compares BioTelemetry and Signal Genetics net margins, return on equity and return on assets.

Summary

BioTelemetry beats Signal Genetics on 7 of the 11 factors compared between the two stocks.

BioTelemetry Company Profile

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segments principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Companys research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Signal Genetics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Companys diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individuals long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Companys MyPRS test provides a whole-genomic expression profile of a patients multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Original post:
Analyzing BioTelemetry (BEAT) and Signal Genetics (MGEN) - The Ledger Gazette

This entry was posted on September 6, 2017 at 7:50 pm and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |